CS McKee’s Biogen BIIB Stock Holding History

CS McKee’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$22M	Sell	74,026 -6,700	-8%	-$1.86M	2.01%	14
2019 Q3	$18.8M	Sell	80,726 -1,214	-1%	-$283K	1.7%	22
2019 Q2	$19.2M	Buy	81,940 +30,530	+59%	+$7.05M	1.69%	22
2019 Q1	$12.2M	Buy	+51,410	New	+$16.2M	1.07%	46

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CS McKee's BIIB Position: Q4 2019 in Review

CS McKee reduced its Biogen (BIIB) stake by 8.3% in Q4 2019, selling an estimated $1.86M and leaving 74,026 shares worth $22M. The position accounts for 2.01% of the portfolio, ranked #14.

CS McKee first reported a position in BIIB in Q1 2019 and has held it in 4 quarters since. 1,102 funds tracked by Wall St. Rank hold BIIB as of Q4 2019.

CS McKee held 74,026 shares of Biogen worth $22M as of Q4 2019.
CS McKee sold 6,700 Biogen shares in Q4 2019, an estimated $1.86M.
Biogen made up 2.01% of CS McKee's portfolio in Q4 2019, its #14 holding.
CS McKee first reported a position in Biogen in Q1 2019 and has held it in 4 quarters since.
1,102 funds tracked by Wall St. Rank held Biogen as of Q4 2019.

Based on CS McKee's 13F filing for Q4 2019, filed 14 Feb 2020.